The Department of Health (DH) today (April 10) endorsed a licensed drug wholesaler, namely Hind Wing Company Limited (Hind Wing), to recall one batch (batch number: VM4608) of Apo-Fluoxetine Capsules 20mg (Hong Kong registration number: HK-68820), from the market as a precautionary measure due to a potential quality issue.
The DH received notification from Hind Wing that the overseas manufacturer of the product is recalling the above batch due to out of trend degradation product test results. As a precautionary measure, Hind Wing is voluntarily recalling the affected batch from the market.
The above product, containing fluoxetine, is a prescription medicine used for the treatment of depression. According to Hind Wing, the affected batch has been imported into Hong Kong and supplied to private hospitals, private doctors and pharmacies.
Hind Wing has set up a hotline (2541 5731) to answer related enquiries.
So far, the DH has not received any adverse reaction reports in connection with the above product. The DH will closely monitor the recall.
Patients who are taking the above product should not stop taking the medicine, but should seek advice from their healthcare professionals as soon as possible for appropriate arrangements.
Reposted from HKSAR Government webpage:
https://www.drugoffice.gov.hk/eps/news/showNews/Apo-Fluoxetine/pharmaceutical_trade/2026-04-10/en/57172.html
- 2026.04.10